About Voltage-dependent calcium channel gamma-2 subunit
Voltage-dependent calcium channel gamma-2 subunit (CACNG2) is a protein
from Homo sapiens identified by UniProt accession
Q9Y698, 323 residues long.
MolForge cross-references it against 0 known binders and
167 disease associations.
Target properties
| Protein name | Voltage-dependent calcium channel gamma-2 subunit |
|---|
| UniProt accession | Q9Y698 |
|---|
| Gene | CACNG2 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 323 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (167)
Diseases linked to this target (Open Targets).
- intellectual disability, autosomal dominant 10 · score 0.49
- cardiovascular disease · score 0.46
- generalized anxiety disorder · score 0.39
- gastrointestinal disease · score 0.37
- Polyuria · score 0.37
- Urinary incontinence · score 0.37
- autosomal dominant non-syndromic intellectual disability · score 0.37
- anxiety · score 0.27
- breast adenocarcinoma · score 0.25
- lung adenocarcinoma · score 0.21
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q9Y698-F1 | alphafold | PREDICTED | 66.55 | — |
Amino-acid sequence (323 residues)
MGLFDRGVQM LLTTVGAFAA FSLMTIAVGT DYWLYSRGVC KTKSVSENET SKKNEEVMTH SGLWRTCCLE GNFKGLCKQI DHFPEDADYE ADTAEYFLRA VRASSIFPIL SVILLFMGGL CIAASEFYKT RHNIILSAGI FFVSAGLSNI IGIIVYISAN AGDPSKSDSK KNSYSYGWSF YFGALSFIIA EMVGVLAVHM FIDRHKQLRA TARATDYLQA SAITRIPSYR YRYQRRSRSS SRSTEPSHSR DASPVGIKGF NTLPSTEISM YTLSRDPLKA ATTPTATYNS DRDNSFLQVH NCIQKENKDS LHSNTANRRT TPV
Explore Voltage-dependent calcium channel gamma-2 subunit with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets